Natasha Daughtrey is a partner in the firm’s Intellectual Property Litigation group. She joined Goodwin in 2011.

Ms. Daughtrey focuses her practice on intellectual property litigation and counseling. Ms. Daughtrey has experience representing companies in all stages of patent litigation from pre-suit investigations through trial and appeals. She also advises clients on patent-related due diligence. Ms. Daughtrey has broad experience litigating in federal courts as well as in proceedings before the United States Patent and Trademark Office, including inter partes reviews. She has worked on cases relating to a variety of different technologies, including pharmaceutical, medical device, transmission lines, software, and cosmetics. Ms. Daughtrey also represents pro bono clients in clemency and immigration related matters.

Ms. Daughtrey is an editor of Goodwin’s Big Molecule Watch blog, dedicated to providing resources and observations through Goodwin’s active watch of the world of biologics, biosimilars, and the Biologics Price Competition and Innovation Act (BPCIA). Ms. Daughtrey is also a key contributor to Goodwin’s Founders Workbench, an online resource for start-ups, emerging companies, and the entrepreneurial community.

Representing Teva in an ongoing patent infringement litigation against Eli Lilly and Company related to Eli Lilly’s application to the FDA to market the antibody galcanezumab for the treatment of migraine.

Represented AMAG Pharmaceuticals in patent infringement action against Sandoz Inc. related to Sandoz’s proposed generic version of Feraheme® (ferumoxytol) for the treatment of iron-deficiency anemia.

Represented an individual in a patent infringement and unfair competition case related to electrical transmission lines.

Represented Actavis in a patent infringement action filed by Valeant Pharmaceuticals Int’l and others under the Hatch-Waxman Act relating to Actavis’s filing of an abbreviated new drug application for generic versions of Valeant’s drug UCERIS®.At trial, the Court granted Actavis’s motion for judgment of non-infringement under Rule 52(c).

Represented Teva in Hatch-Waxman patent infringement litigation brought by Genzyme in response to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of Genzyme’s stem cell mobilizing agent, Mozobil® (plerixafor).

Represented Lupin in patent infringement litigation under the Hatch-Waxman Act in response to Lupin’s filing of an abbreviated new drug application seeking approval to market a generic version of Senju’s Prolensa® (bromfenac ophthalmic solution) medication.

Represented Roxane in a patent infringement litigation filed by Prometheus in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Prometheus’s IBS treatment drug, Lotronex® (alosetron hydrochloride). After a bench trial, the District Court found in favor of Roxane that Prometheus’s patent was invalid.

Professional Experience

Prior to joining Goodwin, Ms. Daughtrey was a Make a Difference Fellow at Brooklyn Legal Services Corporation A in the Individual Housing Unit where she represented tenants and tenant associations in housing litigation and appeals.

During law school, Ms. Daughtrey was a judicial intern to the Honorable Ronald M. Whyte, U.S. District Court for the Northern District of California and as a legal intern with the U.S. Attorney’s Office for the Southern District of California in the Civil Division. She was a member of San Diego Law Review.

Ms. Daughtrey is a member of the New York City Bar Association Patents Committee, and a member of the New York Intellectual Property Law Association.

Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.